Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 13Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma 2571Precursor Cell Lymphoblastic Leukemia-Lymphoma 2086Lymphoma, Non-Hodgkin 2058Leukemia, Lymphocytic, Chronic, B-Cell 1771Lymphoma, Follicular 1652Lymphoma, Large B-Cell, Diffuse 1597Leukemia 1172Hodgkin Disease 1128Lymphoma, Mantle-Cell 1110Burkitt Lymphoma 887Leukemia, Myeloid, Acute 885Lymphoma, B-Cell, Marginal Zone 788Recurrence 779Multiple Myeloma 744Lymphoma, B-Cell 704Myelodysplastic Syndromes 615Neoplasms 494Lymphoma, T-Cell, Cutaneous 479Waldenstrom Macroglobulinemia 470Lymphoma, Large-Cell, Immunoblastic 456Mycosis Fungoides 383Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 382Lymphoma, Large-Cell, Anaplastic 362Sezary Syndrome 321Lymphoma, T-Cell, Peripheral 321Leukemia, Myelogenous, Chronic, BCR-ABL Positive 307Hematologic Neoplasms 299Myeloproliferative Disorders 288Neoplasms, Plasma Cell 270Blast Crisis 261

Interventions

ibrutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hepatitis B, Chronic × Lymphoid × Clear all
NCT02991638 2018-04-12

Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers

The University of Hong Kong

Phase 3 Unknown
62 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Hepatitis B, Chronic, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡